Cantor Fitzgerald maintains Overweight on ORIC stock
Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to InvestingPro data ...
ETF Daily News26d
Cantor Fitzgerald Predicts ORIC FY2025 Earnings
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for ORIC Pharmaceuticals in a report ...
Cantor says Oric accidental release looks ‘very positive’ for mevrometostat
Cantor Fitzgerald notes that the firm discovered “what appears” to be an “accidental release” of a snippet on the ASCO-GU daily news website ...
Investing8d
Cantor Fitzgerald maintains Overweight on ORIC stock
On Monday, Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to ...
Business Insider8d
Cantor says Oric accidental release looks ‘very positive’ for mevrometostat
Cantor Fitzgerald notes that the firm discovered ... the high-level news commentary “sounds very positive” for mevrometostat and Oric Pharmaceuticals (ORIC). The firm has an Overweight ...